Reduced intensity conditioning with high-dose rituximab followed by allogeneic transplantation of hematopoietic cells for the treatment of relapsed/refractory B-cell non Hodgkin's lymphomas
Latest Information Update: 15 Feb 2018
At a glance
- Drugs Rituximab (Primary)
- Indications B-cell lymphoma
- Focus Therapeutic Use
- 15 Feb 2018 Status changed from recruiting to completed.
- 09 Oct 2013 New trial record